Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effectiveness of an NK1 Antagonist in PTSD.

Trial Profile

Effectiveness of an NK1 Antagonist in PTSD.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2013

At a glance

  • Drugs Vofopitant (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 11 Mar 2013 Additional lead trial centre added as reported by ClinicalTrials.gov record.
    • 14 Apr 2009 Planned number of patients changed from 52 to 47, additional lead trial centre identified, actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 14 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top